The following information was obtained through the clinical study (b)(6).It was reported the physician implanted a 44m gore® cordiform asd occluder on (b)(6) 2018.At one year follow-up visit on (b)(6) 2019, subject reported experiencing palpitations since six month visit, similar to what she experienced pre-procedure.Subject was provided with a zio-patch x3 days to monitor.Supraventricular arrhythmia was noted on (b)(6) 2019 on zio-patch monitor.Rate control medication was initiated on (b)(6) 2019 and is ongoing.
|
G5: pma/510k#: p050006.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any "defects" or has "malfunctioned".These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|